Table 1.
Patient background characteristics (full analysis set)
| Characteristic | Overall (N = 178) | PA21 750-mg group (N = 39) |
PA21 1500-mg group (N = 35) |
PA21 2250-mg group (N = 33) |
PA21 3000-mg group (N = 34) |
Placebo group (N = 37) |
|---|---|---|---|---|---|---|
| Sex | ||||||
| Men | 115 (64.6) | 27 (69.2) | 23 (65.7) | 23 (69.7) | 19 (55.9) | 23 (62.2) |
| Women | 63 (35.4) | 12 (30.8) | 12 (34.3) | 10 (30.3) | 15 (44.1) | 14 (37.8) |
| Age (years) | 61.4 ± 10.9 | 59.4 ± 10.4 | 63.8 ± 12.0 | 61.9 ± 10.5 | 61.4 ± 11.2 | 60.8 ± 10.2 |
| Primary disease (n) | ||||||
| Diabetic nephropathy | 52 | 14 | 9 | 5 | 10 | 14 |
| Chronic glomerulonephritis | 56 | 12 | 8 | 11 | 14 | 11 |
| Nephrosclerosis | 23 | 7 | 6 | 6 | 1 | 3 |
| Polycystic kidney disease | 10 | 2 | 2 | 2 | 1 | 3 |
| Chronic pyelonephritis | 1 | 0 | 0 | 1 | 0 | 0 |
| Others | 11 | 0 | 2 | 3 | 3 | 3 |
| Unknown | 26 | 4 | 8 | 6 | 5 | 3 |
| Mode of dialysis | ||||||
| Hemodialysis | 176 (98.9) | 38 (97.4) | 35 (100.0) | 32 (97.0) | 34 (100.0) | 37 (100.0) |
| Hemodiafiltration | 2 (1.1) | 1 (2.6) | 0 (0) | 1 (3.0) | 0 (0) | 0 (0) |
| Dialysis vintage (months) | 83.7 ± 63.5 | 77.6 ± 67.5 | 85.1 ± 60.7 | 95.8 ± 81.9 | 91.5 ± 58.6 | 71.0 ± 45.0 |
| Serum phosphorus (mg/dL) | 7.46 ± 1.22 | 7.36 ± 1.18 | 7.69 ± 1.32 | 7.42 ± 0.87 | 7.57 ± 1.33 | 7.26 ± 1.35 |
| Corrected serum calcium (mg/dL) | 8.60 ± 0.56 | 8.49 ± 0.46 | 8.65 ± 0.52 | 8.59 ± 0.66 | 8.69 ± 0.52 | 8.58 ± 0.61 |
| Intact parathyroid hormone (pg/mL) | 285.3 ± 151.1 | 277.9 ± 148.9 | 262.1 ± 139.7 | 345.0 ± 176.1 | 262.8 ± 143.3 | 282.4 ± 140.5 |
Data are presented as n (%) or mean ± SD, unless otherwise stated
Fisher’s exact text was used to determine differences in sex. One-way analysis of variance was used to determine differences in age and serum phosphorus, calcium, and intact parathyroid hormone levels between the groups